Sandler et al, in a systematic review of the safety of VEGF inhibitors in patients with NSCLC and brain involvement, found no increased risk of intracerebral bleeding compared to patients who had not received anti-angiogenic therapy (70). This evidence concerns the gene VEGFA and non-small cell lung carcinoma.